These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 9387247)

  • 1. [CD4+ T-cell immunity and Ab responses to mutant ras protein in pancreas and colon cancer patients].
    Qin H; Chen W; Takahashi M
    Zhonghua Zhong Liu Za Zhi; 1996 May; 18(3):173-6. PubMed ID: 9387247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients.
    Qin H; Chen W; Takahashi M; Disis ML; Byrd DR; McCahill L; Bertram KA; Fenton RG; Peace DJ; Cheever MA
    Cancer Res; 1995 Jul; 55(14):2984-7. PubMed ID: 7606715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody to ras proteins in patients with colon cancer.
    Takahashi M; Chen W; Byrd DR; Disis ML; Huseby ES; Qin H; McCahill L; Nelson H; Shimada H; Okuno K
    Clin Cancer Res; 1995 Oct; 1(10):1071-7. PubMed ID: 9815896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
    Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
    Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer.
    Kubuschok B; Neumann F; Breit R; Sester M; Schormann C; Wagner C; Sester U; Hartmann F; Wagner M; Remberger K; Schilling M; Pfreundschuh M
    Clin Cancer Res; 2006 Feb; 12(4):1365-72. PubMed ID: 16489095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of linear and branched peptide forms (MAPs) in the induction of T helper responses to point-mutated ras immunogens.
    Schott ME; Wells DT; Schlom J; Abrams SI
    Cell Immunol; 1996 Dec; 174(2):199-209. PubMed ID: 8954620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant ras epitopes as targets for cancer vaccines.
    Abrams SI; Hand PH; Tsang KY; Schlom J
    Semin Oncol; 1996 Feb; 23(1):118-34. PubMed ID: 8607022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
    Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
    Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
    Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell recognition of a point mutation in the P21 Ras protein.
    Yin L; Lowe P; Stauss HJ
    Leukemia; 1993 Aug; 7 Suppl 2():S27-30. PubMed ID: 7689674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive and negative consequences of soluble Fas ligand produced by an antigen-specific CD4(+) T cell response in human carcinoma immune interactions.
    Bergmann-Leitner ES; Abrams SI
    Cell Immunol; 2001 Apr; 209(1):49-62. PubMed ID: 11414736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
    Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
    Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl.
    Cheever MA; Chen W; Disis ML; Takahashi M; Peace DJ
    Ann N Y Acad Sci; 1993 Aug; 690():101-12. PubMed ID: 8103658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination.
    Gjertsen MK; Saeterdal I; Thorsby E; Gaudernack G
    Br J Cancer; 1996 Dec; 74(11):1828-33. PubMed ID: 8956801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer.
    Seiden-Long IM; Brown KR; Shih W; Wigle DA; Radulovich N; Jurisica I; Tsao MS
    Oncogene; 2006 Jan; 25(1):91-102. PubMed ID: 16158056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease.
    Suzuki H; Graziano DF; McKolanis J; Finn OJ
    Clin Cancer Res; 2005 Feb; 11(4):1521-6. PubMed ID: 15746055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA.
    Marchese R; Muleti A; Pasqualetti P; Bucci B; Stigliano A; Brunetti E; De Angelis M; Mazzoni G; Tocchi A; Brozzetti S
    Pancreas; 2006 Mar; 32(2):171-7. PubMed ID: 16552337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of CD4(+) and CD8(+) Bordetella pertussis toxin subunit S1 specific T cells by immunization with synthetic peptides.
    Fagerberg J; Askelöf P; Wigzell H; Mellstedt H
    Cell Immunol; 1999 Sep; 196(2):110-21. PubMed ID: 10527563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptides designed from molecular modeling studies of the ras-p21 protein induce phenotypic reversion of a pancreatic carcinoma cell line but have no effect on normal pancreatic acinar cell growth.
    Kanovsky M; Michl J; Botzolaki G; Morin J; Kovac C; Chung DL; Chie L; Friedman FK; Pincus MR
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):202-8. PubMed ID: 12783204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome.
    Carbone DP; Ciernik IF; Kelley MJ; Smith MC; Nadaf S; Kavanaugh D; Maher VE; Stipanov M; Contois D; Johnson BE; Pendleton CD; Seifert B; Carter C; Read EJ; Greenblatt J; Top LE; Kelsey MI; Minna JD; Berzofsky JA
    J Clin Oncol; 2005 Aug; 23(22):5099-107. PubMed ID: 15983396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.